The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure : Optimization of the Complex Treatment of Nonischemic Dilated Cardiomyopathy Due to the Addition to the Standard Drug Therapy of Intracoronary Administration of Umbilical Cord-derived Mesenchymal Stromal Cells
The purpose of this study is to optimize the complex treatment of non-ischemic dilated cardiomyopathy by supplementing the standard drug therapy with intracoronary administration of umbilical cord-derived mesenchymal stromal cells.Sixty patients will be selected and randomly divided into the main and control groups in a 1: 1 ratio.Patients of the main group will receive complex treatment based on the addition to the standard drug therapy of intracoronary administration of 10 million mesenchymal stromal cells of the umbilical cord, and patients of the control group will receive only standard drug therapy.Every patient will maintain their standard treatment of chronic heart failure, with maximum tolerated dosage without side effects.The day of infusion will be considered day zero. From that moment, followup will be divided into 0-1,1-3 and 3-6 months.Clinical results will be analyzed after completion of 6 months of followup..
Medienart: |
Klinische Studie |
---|
Erscheinungsjahr: |
2023 |
---|---|
Erschienen: |
2023 |
Enthalten in: |
ClinicalTrials.gov - (2023) vom: 01. Mai Zur Gesamtaufnahme - year:2023 |
---|
Sprache: |
Englisch |
---|
Links: |
Volltext [kostenfrei] |
---|
Themen: |
610 |
---|
Anmerkungen: |
Source: Link to the current ClinicalTrials.gov record., First posted: March 27, 2020, Last downloaded: ClinicalTrials.gov processed this data on May 10, 2023, Last updated: May 10, 2023 |
---|
Study ID: |
NCT04325594 |
---|---|
Veröffentlichungen zur Studie: |
|
fisyears: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
CTG003343693 |
---|
LEADER | 01000caa a22002652 4500 | ||
---|---|---|---|
001 | CTG003343693 | ||
003 | DE-627 | ||
005 | 20230510105539.0 | ||
007 | cr uuu---uuuuu | ||
008 | 210408s2023 xx |||||o 00| ||eng c | ||
035 | |a (DE-627)CTG003343693 | ||
035 | |a (UBBS_Klinische_Studien)NCT04325594 | ||
035 | |a (UBBS_Klinische_Studien)RCCCT 02-02-2020 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
245 | 1 | 0 | |a The Application of the Umbilical Cord Mesenchymal Stem Cells in the Complex Treatment of Non-ischemic Heart Failure |b Optimization of the Complex Treatment of Nonischemic Dilated Cardiomyopathy Due to the Addition to the Standard Drug Therapy of Intracoronary Administration of Umbilical Cord-derived Mesenchymal Stromal Cells |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Source: Link to the current ClinicalTrials.gov record., First posted: March 27, 2020, Last downloaded: ClinicalTrials.gov processed this data on May 10, 2023, Last updated: May 10, 2023 | ||
520 | |a The purpose of this study is to optimize the complex treatment of non-ischemic dilated cardiomyopathy by supplementing the standard drug therapy with intracoronary administration of umbilical cord-derived mesenchymal stromal cells.Sixty patients will be selected and randomly divided into the main and control groups in a 1: 1 ratio.Patients of the main group will receive complex treatment based on the addition to the standard drug therapy of intracoronary administration of 10 million mesenchymal stromal cells of the umbilical cord, and patients of the control group will receive only standard drug therapy.Every patient will maintain their standard treatment of chronic heart failure, with maximum tolerated dosage without side effects.The day of infusion will be considered day zero. From that moment, followup will be divided into 0-1,1-3 and 3-6 months.Clinical results will be analyzed after completion of 6 months of followup. | ||
650 | 2 | |a Heart Failure | |
650 | 2 | |a Cardiomyopathies | |
650 | 2 | |a Cardiomyopathy, Dilated | |
650 | 4 | |a Study Type: Interventional | |
650 | 4 | |a Recruitment Status: Completed | |
650 | 4 | |a Phase: Phase 2 | |
650 | 4 | |a 610 | |
773 | 0 | 8 | |i Enthalten in |t ClinicalTrials.gov |g (2023) vom: 01. Mai |
773 | 1 | 8 | |g year:2023 |g day:01 |g month:05 |
856 | 4 | 0 | |u https://clinicaltrials.gov/show/NCT04325594 |z kostenfrei |3 Volltext |
912 | |a GBV_CTG | ||
951 | |a AR | ||
952 | |j 2023 |b 01 |c 05 |